Avid Bioservices Inc (CDMO)

[entdoc]

FTM, I don't think I've seen Thorpe commit to print so strongly as, "Bavituximab is a monoclonal antibody that is proving safe and effective as a second-line therapy in advanced lung cancer patients."
Agreewith you that late-stage cancer patient immune systems are in bad shape, certainly worse than those with early cancers. As you said, "their immune systems are very suppressed". I can’t remember if lower animal studies were performed comparing Bavi- alone, and Bavi with Docetaxel, vs. Docetaxel alone, or Bavi in untreated (by chemotherapy)vs.treated. Cancers are metabolic “sinks” that parasitize cellular building blocks, and detract from the body’s ability to reproduce healthy cells of all kinds, whether M1 monocytes, T-lymphocytes, or neutrophils, My fixation here on “less sick“ patients using Bavi- anticipates its use in very early cancers, and non-malignant diseases such as systemic lupus and other auto-immune diseases which are -PS affected but the patients are less ill, capable of significant anabolic activity, hopefully having not been treated previously or concurrently with cytotoxic agents.